endothelial progenitor cells
Cell therapyexperimental
Endothelial progenitor cell is a term that has been applied to multiple different cell types that play roles in the regeneration of the endothelial lining of blood vessels. Outgrowth endothelial cells are an EPC subtype committed to endothelial cell formation. Despite the history and controversy, the EPC in all its forms remains a promising target of regenerative medicine research. — Wikipedia
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2016 (NCT02805023)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Stem CellSupplementation
Stem Cell supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEndothelial progenitor cell ↗
Also known as
- endothelial progenitor cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06359912 | Phase 1 | Apr 30, 2024 | Allife Medical Science and Technology Co., Ltd., Jiao Tong University |
| NCT05993884 | Phase 1 | Aug 15, 2023 | Allife Medical Science and Technology Co., Ltd. |
| NCT04187625 | Early Phase 1 (Phase 1) | Jan 1, 2020 | Harvard University |
| NCT02805023 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2016 | BioGenCell Ltd., Laniado Medical Center |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allife Medical Science and Technology Co., Ltd. | For profit | 2 | 2 | 1 | 2023 |
| BioGenCell Ltd. | For profit | 1 | 1 | 1 | 2016 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Laniado Medical Center | Academic/Hospital | 1 | 0 | 1 | 2016 |
5 organizations
Page 1 / 1